Jiangxi Fushine Pharmaceutical300497.SZValuation Analysis

As of Oct 19, 2026, Jiangxi Fushine Pharmaceutical (300497.SZ) trades at a P/E of 60.00x, P/B of 3.28x, P/S of 4.36x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 80th percentile over the trailing 10Y window (vs. 5th percentile over 3Y); P/B sits at the 47th percentile over the trailing 10Y window (vs. 66th percentile over 3Y); P/S sits at the 40th percentile over the trailing 10Y window (vs. 41st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 66th percentile within its industry and the 66th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B percentiles diverge here, differing by 33.2 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Jiangxi Fushine Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.